Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2010
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:M04AX07
|
| gptkbp:CASNumber |
gptkb:76801-97-1
|
| gptkbp:contraindication |
gptkb:G6PD_deficiency
|
| gptkbp:effect |
lowers serum uric acid
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
gptkb:pegloticase
|
| gptkbp:halfLife |
10-12 days
|
| gptkbp:indication |
treatment of chronic gout
|
| gptkbp:KEGGID |
D08913
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Horizon_Therapeutics
|
| gptkbp:mechanismOfAction |
uricase enzyme
|
| gptkbp:MedlinePlusID |
a611009
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
gptkb:DB05509
none |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:RxNorm |
1114972
|
| gptkbp:sideEffect |
anaphylaxis
infusion reaction gout flare |
| gptkbp:target |
uric acid
|
| gptkbp:UNII |
QX9K0X4Q8P
|
| gptkbp:bfsParent |
gptkb:Horizon_Therapeutics
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Krystexxa
|